CHRS FY 2020 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$476M+33.6% YoY

Gross Profit

$438M92.1% margin

Operating Income

$156M32.9% margin

Net Income

$132M27.8% margin

EPS (Diluted)

$1.62

Cash Flow

Operating Cash Flow

$154M

Free Cash Flow

$147M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$842M

Total Liabilities

$561M

Stockholders' Equity

$281M

Cash & Equivalents

$541M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$476M	$356M	+33.6%
Gross Profit	$438M	$339M	+29.3%
Operating Income	$156M	$108M	+45.1%
Net Income	$132M	$90M	+47.2%